A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors.

Tolcher, A W; Bendell, J C; Papadopoulos, K P; Burris, H A; Patnaik, A; Jones, S F; Rasco, D; Cox, D S; Durante, M; Bellew, K M; Park, J; Le, N T; Infante, J R

Tolcher, A W; Bendell, J C; Papadopoulos, K P; Burris, H A; Patnaik, A; Jones, S F; Rasco, D; Cox, D S; Durante, M; Bellew, K M; Park, J; Le, N T; Infante, J R.

Affiliation

Tolcher AW; South Texas Accelerated Research Therapeutics LLC, San Antonio. Electronic address: atolcher@start.stoh.com.
Bendell JC; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.
Papadopoulos KP; South Texas Accelerated Research Therapeutics LLC, San Antonio.
Burris HA; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.
Patnaik A; South Texas Accelerated Research Therapeutics LLC, San Antonio.
Jones SF; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.
Rasco D; South Texas Accelerated Research Therapeutics LLC, San Antonio.
Cox DS; GlaxoSmithKline, Collegeville.
Durante M; GlaxoSmithKline, Collegeville.
Bellew KM; Pharmaceutical Companies of Johnson and Johnson, Greater Philadelphia Area.
Park J; GlaxoSmithKline, Collegeville.
Le NT; Novartis, East Hanover, USA.
Infante JR; Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville.

Ann Oncol ; 26(1): 58-64, 2015 Jan.

Article in En | MEDLINE | ID: mdl-25344362

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/therapeutic use; Neoplasms/drug therapy; Protein Kinase Inhibitors/therapeutic use; Pyridones/therapeutic use; Pyrimidinones/therapeutic use; Sirolimus/analogs & derivatives; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics; Drug Administration Schedule; Everolimus; Female; Humans; MAP Kinase Kinase 1/antagonists & inhibitors; MAP Kinase Kinase 2/antagonists & inhibitors; Male; Middle Aged; Protein Kinase Inhibitors/adverse effects; Protein Kinase Inhibitors/pharmacokinetics; Pyridones/adverse effects; Pyridones/pharmacokinetics; Pyrimidinones/adverse effects; Pyrimidinones/pharmacokinetics; Sirolimus/adverse effects; Sirolimus/pharmacokinetics; Sirolimus/therapeutic use; TOR Serine-Threonine Kinases/antagonists & inhibitors; Treatment Outcome; Young Adult

Key words

MEK inhibitor; advanced solid tumors; everolimus; mTOR inhibitor; pancreatic cancer; trametinib

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 3_ND Database: MEDLINE Main subject: Pyridones / Pyrimidinones / Antineoplastic Combined Chemotherapy Protocols / Sirolimus / Protein Kinase Inhibitors / Neoplasms Limits: Adolescent / Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Ann Oncol Year: 2015 Document type: Article

Fulltext

XML

PubMed Links

Search on Google